APIM

AcronymDefinition
APIMActor-Partner Interdependence Model (relationships)
APIMAsia Pacific Institute of Management (India; also seen as AIM)
APIMAssociação Promotora da Instrução dos Macaenses (Macau, China)
APIMAsian Partnership on International Migration (India)
APIMATM Port Interface Modules (Sprint)
APIMAssociation Professionnelle Internationale des Medicins
References in periodicals archive ?
Finally, the APIM was utilized to explore possible actor and partner effects across the study variables, as noted in Table 4.
An over-time APIM without measurement of the partner effects (due to the couples-based discrepancy score) was conducted to analyze the third research question of interest: the impact of couple sexual desire discrepancy on quality of the sexual experience at the event level (see Figure 2).
Over-time APIM fixed actor and partner effects predicting quality of sexual experience with individual sexual desire Standard Estimate Error DF t Women Actor Effect .
APIM Therapeutics AS Kadmon Pharmaceuticals, LLC centrose llc Immodulon Therapeutics Ltd.
The investment is led by Norsk Innovasjonskapital III AS, a leading Norwegian VC firm in syndication with existing APIM investors, Sarsia Seed (Bergen, Norway), Birk Venture and Ro Invest (Oslo, Norway).
Konstantinos Alevizopoulos, CEO of APIM Therapeutics: "We are delighted to have secured this additional funding in APIM Therapeutics which will allow for further preclinical development of our novel therapeutic concept".
The follow-up investment is provided by Birk Venture and Ro Invest, two early stage investment companies located in Oslo, Norway, and Sarsia Seed, a seed stage investor that has already led two investment transactions in APIM Therapeutics.
Konstantinos Alevizopoulos, CEO of APIM Therapeutics:" We are delighted to have secured this additional funding in APIM Therapeutics which will allow for the further development of our novel therapeutic concept towards first-in-man clinical trials".
Their equal enthusiasm for the company and its exceptional offering, further consolidates our belief in APIM Therapeutics.
TRONDHEIM, Norway, March 21, 2011 /PRNewswire/ -- APIM Therapeutics AS, an early-stage Norwegian therapeutic company, is pursuing a novel drug approach with the ability to potentiate the action of a wide range of chemotherapeutic drugs currently used to treat several types of cancer.
This is the second seed investment by Sarsia Seed to APIM Therapeutics to-date.
Konstantinos Alevizopoulos, CEO of APIM Therapeutics:"We are delighted that Sarsia Seed has provided this follow-up funding, which is a vote of confidence in the company's results so far.